{"prompt": "['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', 'Table 3: Adverse Event Definitions', 'Adverse Event (AE)', 'Any untoward medical occurrence in a clinical trial participant', 'administered a medicinal product and which does not', 'necessarily have a causal relationship with this product.', 'Adverse Reaction (AR)', 'Any untoward and unintended response to an investigational', 'medicinal product related to any dose administered', 'This includes medication errors, uses outside of protocol', '(including misuse and abuse of product)', 'Unexpected Adverse Reaction', 'An adverse reaction, the nature or severity of which is not', '(UAR)', 'consistent with the applicable product information (eg', \"Investigator's Brochure for an unauthorised product or\", 'summary of product characteristics (SPC) for an authorised', 'product.', 'Serious Adverse Event (SAE) or', 'Any AE or AR that at any dose:', 'Serious Adverse Reaction (SAR)', 'results in death', 'is life threatening*', 'requires', 'hospitalisation', 'or', 'prolongs', 'existing', 'hospitalisation*', 'results in persistent or significant disability or incapacity', 'is a congenital anomaly or birth defect', 'or is another important medical condition**', 'SUSAR', 'Suspected Unexpected Serious Adverse Reaction', '* the term life threatening here refers to an event in which the participant is at risk of death at the', 'time of the event; it does not refer to an event that might hypothetically cause death if it was more', 'severe (e.g., a silent myocardial infarction)', '** Hospitalisation is defined as an in-patient admission, regardless of length of stay, even if the', 'hospitalisation is a precautionary measure for continued observation. Hospitalisation for pre-', 'existing conditions (including elective procedures that have not worsened) do not constitute an SAE', '*** Medical judgement should be exercised in deciding whether an AE or AR is serious in other', 'situations. Important AEs or ARs that may not be immediately life threatening or result in death or', 'hospitalisation but may seriously jeopardise the participant by requiring intervention to prevent', 'one of the other outcomes listed in the table (e.g., a secondary malignancy, an allergic', 'bronchospasm requiring intensive emergency treatment, seizures or blood dyscrasias that do not', 'require hospitalisation, or development of drug dependency).', 'Adverse events include:', 'an exacerbation of a pre-existing illness', 'an increase in the frequency or intensity of a pre-existing episodic event or condition', 'a condition (regardless of whether PRESENT prior to the start of the trial) that is DETECTED', 'after trial drug administration. (This does not include pre-existing conditions recorded as such', 'at baseline - as they are not detected after trial drug administration.)', 'continuous persistent disease or a symptom present at baseline that worsens following ATIMP', 'administration', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 51 of 68']['MEIRAGTx', 'CNGA3CNGA3 Gene Therapy trial for Achromatopsia', 'Adverse events do NOT include:', 'Medical or surgical procedures: the condition that leads to the procedure is the adverse event', 'Pre-existing disease or a condition present before ATIMP administration that does not worsen', 'Hospitalisation where no untoward or unintended response has occurred e.g. elective', 'cosmetic surgery', 'Overdose of medication without signs or symptoms', '5.11.3.2', 'Other Notifiable Adverse Events', 'In order to manage the safety risks associated with administration of the ATIMP, all safety events will', 'be reviewed within a short time frame for all participants, as described in the CNGA3 Gene Therapy', 'Trial for Achromatopsia Data Management Plan.', 'Pregnancy is the only additional notifiable event that requires expedited reporting.', '5.11.3.3', 'Procedures to follow in the event of female participants becoming pregnant', 'A pregnancy test will be conducted for all females of childbearing age who are sexually active, and the', 'results will be recorded in the medical notes before enrolling a volunteer to the trial. Females with a', 'positive pregnancy test at this point will be excluded from the trial.', 'Where appropriate, a further pregnancy test will be performed on the day of administration of the', 'ATIMP. Female participants with a positive pregnancy test at this point will be excluded from the trial', 'prior to administration of the ATIMP.', 'Although participants are instructed to use double barrier contraception, we cannot exclude entirely', 'that a participant might become pregnant after administration of the ATIMP. In the unlikely event that', 'a participant is found to be pregnant we will notify their GP that she is participating in a gene therapy', 'trial and that, although the risks involved are minimal, there is a chance of gene transfer to the unborn', \"child. With the participant's consent, we will ask the GP/obstetrician to provide us with regular reports\", 'about the pregnancy until delivery. The pregnancy will be reported to the pharmacovigilance service', 'provider on a pregnancy report form within 24 hours of the investigator becoming aware of the event.', 'The participant will continue to be assessed until outcome of the pregnancy. However, if the', 'participant is unable or unwilling to participate further in the trial, she will be encouraged to continue', 'clinical monitoring visits to assess ocular health. In this situation, we may choose to enrol another', 'participant to ensure the scientific validity of the trial.', '5.11.3.4', 'Procedures to follow in the event of the partners of male participants', 'becoming pregnant', 'Although participants are instructed to use double barrier contraception, we cannot exclude entirely', 'that the partner of a participant might become pregnant after administration of the ATIMP. In the', \"unlikely event that this occurs we will notify the participant's GP that he is participating in a gene\", 'therapy trial and that, although the risks involved are minimal, there is a chance of gene transfer to', \"the unborn child. With the participant's consent, we will request the partner to contact us to ascertain\", 'the status of the pregnancy and the outcome. The pregnancy will be reported to PV Service Provider', 'on a pregnancy report form within 24 hours of the investigator becoming aware of the event.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 52 of 68']\n\n###\n\n", "completion": "END"}